Table 1.

Monotherapy in the second-line setting and beyond

Trial name	Phase	Histology	Therapy	mPFS	1-Year PFS	mORR	Ref
KEYNOTE-001	I/II	All	PEMBRO 2Q3W, 10Q3W, 10Q2W	NR	NR	15%, 25%, 21%	10
KEYNOTE-010	II/III	All	PEMBRO 2 (PD-L1+)	3.9 months	NR	NR	13
				mOS	1-Year OS	DOR
			PEMBRO 2Q3W, 10Q3W, 10Q2W	NR	NR	NR
			PEMBRO 2 (PD-L1+)	9.4 months (14.9)	NR	NR

Note: Completed trials in NSCLC.

Abbreviations: mPFS, median progression-free survival; PEMBRO, pembrolizumab; NR, not reported; PD-L1, programmed death L1; mOS, median overall survival; NSCLC, non-small-cell lung cancer; mORR, median overall response rate; DOR, duration of response.